SCHEMBL17287752

SCHEMBL17287752

O=C(Cc1ccc(Cl)c(Cl)c1)Nc1nc2ccc(OC(F)(F)F)cc2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 16/20 1.00
WNT3A P56704 1/20 0.65
DYRK1A Q13627 1/20 0.62
HDAC3 O15379 1/20 0.62
HDAC4 P56524 1/20 0.62
HDAC1 Q13547 1/20 0.62
HDAC7 Q8WUI4 1/20 0.62
HDAC2 Q92769 1/20 0.62
HDAC10 Q969S8 1/20 0.62
HDAC11 Q96DB2 1/20 0.62
HDAC8 Q9BY41 1/20 0.62
HDAC6 Q9UBN7 1/20 0.62
HDAC9 Q9UKV0 1/20 0.62
HDAC5 Q9UQL6 1/20 0.62
RIPK1 Q13546 1/20 0.55
RIPK3 Q9Y572 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17287679 0.87 CSNK1D (1.00) CSNK1DWNT3ADYRK1AHDAC3HDAC4
SCHEMBL17287700 0.87 CSNK1D (1.00) CSNK1DWNT3A
SCHEMBL17287696 0.85 CSNK1D (1.00) CSNK1D
SCHEMBL17287791 0.85 CSNK1D (1.00) CSNK1DDYRK1A
SCHEMBL15272025 0.81 DYRK1A (0.72) CSNK1DWNT3ADYRK1AHDAC3HDAC4
SCHEMBL30522063 0.81 DYRK1A (0.72) CSNK1DWNT3ADYRK1AHDAC3HDAC4
SCHEMBL21729400 0.81 DYRK1A (0.76) CSNK1DWNT3ADYRK1AHDAC3HDAC4
SCHEMBL29095935 0.81 DYRK1A (0.72) CSNK1DWNT3ADYRK1AHDAC3HDAC4
SCHEMBL17287571 0.80 CSNK1D (1.00) CSNK1DWNT3ADYRK1AHDAC3HDAC4
SCHEMBL24729395 0.80 CSNK1D (0.70) CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9592224-B2 Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases DONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2017-03-14 US claimed
US-20150352082-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2015-12-10 US claimed
EP-2949651-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES Consejo Superior De Investigaciones Científicas (CSIC) (ES) 2015-12-02 EP claimed
EP-3348550-B1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CONSEJO SUPERIOR INVESTIGACION (ES) 2019-04-24 EP disclosed
EP-3348550-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2018-07-18 EP disclosed
US-9592224-B2 Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases DONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2017-03-14 US disclosed
US-20150352082-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2015-12-10 US disclosed
EP-2949651-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES Consejo Superior De Investigaciones Científicas (CSIC) (ES) 2015-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150352082-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CSNK1A1, CRY1, CSNK1G1 CSNK1D 13/4885WNT3A 1982/4885DYRK1A 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.